Skip to main content
Andrea Figueras on Muck Rack

Andrea Figueras

Verified
Barcelona, Catalonia
As seen in: Dow Jones Newswires, The Wall Street Journal, MSN, El País, The Wall Street Journal (China), The Wall Street Journal (Japan), Yahoo Finance, MarketWatch, Flipboard, Mint, Trading View, Yahoo and
Periodista @WSJ @DowJones ✉️ andrea.figueras@wsj.com. Membre de la Junta de Govern de @periodistes_cat. Abans @AFP LATAM, @el_pais, @agenciaacn i @cugatmedia

Get in touch with Andrea

Contact Andrea, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Hugo Boss Urges Shareholders to Reject Frasers’ $2.2 Billion Takeover Bid

|
By Andrea Figueras Verified
| The Wall Street Journal Verified
Frasers last month said it intended to acquire the 73.42% stake in Hugo Boss it didn’t already own Hugo Boss said that it remained focused on its growth plan. valentyn ogirenko/Reuters Hugo Boss asked its shareholders to reject Frasers Group’s FRAS 1.56%increase; up pointing triangle $2.2 billion takeover bid, saying it undervalued the German fashion company, which is pursuing its own growth plan.
Open in Who Shared Issue with article?

AstraZeneca, Ionis shares slide after Wainua misses target in heart disease trial

|
By Andrea Figueras Verified, Connor Hart Verified
| MSN Verified
Andrea Figueras, Connor Hart Shares of AstraZeneca and Ionis Pharmaceuticals tumbled after the companies reported that their drug Wainua failed to meet the primary target in a late-stage clinical trial for heart disease. AstraZeneca and Ionis said the drug didn't meet its primary objective in a Phase 3 trial when treating transthyretin amyloid cardiomyopathy, a rare type of heart disease.
Open in Who Shared View Duplicates (9) Issue with article?

AstraZeneca, Ionis Shares Slide After Wainua Misses Target in Heart Disease Trial

|
By Andrea Figueras Verified, Connor Hart Verified
| The Wall Street Journal Verified
Shares of AstraZeneca AZN -9.00 %decrease; down pointing triangle and Ionis Pharmaceuticals IONS -18.58 %decrease; down pointing triangle tumbled after the companies reported that their drug Wainua failed to meet the primary target in a late-stage clinical trial for heart disease. AstraZeneca and Ionis said the drug didn’t meet its primary objective in a Phase 3 trial when treating transthyretin amyloid cardiomyopathy, a rare type of heart disease.
Open in Who Shared Issue with article?
See all 2,433 licensed articles (2,596 Total)